---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-039488"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2026-08-20T20:45:25+00:00"
generated_at: "2026-08-20T20:46:03.189435+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals appoints James Liddy as director effective August 19, 2026

## Summary
- Board approved James Liddy as director on August 19, 2026, effective immediately.
- No arrangements or understandings exist with any person regarding Liddy's selection.
- No transactions involving Hepion and Liddy required under Item 404(a) of Reg S-K.
- Form signed by interim CEO Gary Stetz on August 20, 2026.

## SEC filing metadata
- accession: 0001493152-26-039488
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2026-08-20T20:45:25+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/0001493152-26-039488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-039488
- JSON: https://secwatch.observer/filing/0001493152-26-039488.json
- Plain text: https://secwatch.observer/filing/0001493152-26-039488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.